Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. / Magkos, Faidon; Su, Xiong; Bradley, David; Fabbrini, Elisa; Conte, Caterina; Eagon, J Christopher; Varela, J Esteban; Brunt, Elizabeth M; Patterson, Bruce W; Klein, Samuel.
In: Gastroenterology, Vol. 142, No. 7, 2012, p. 1444-1446.e2.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects
AU - Magkos, Faidon
AU - Su, Xiong
AU - Bradley, David
AU - Fabbrini, Elisa
AU - Conte, Caterina
AU - Eagon, J Christopher
AU - Varela, J Esteban
AU - Brunt, Elizabeth M
AU - Patterson, Bruce W
AU - Klein, Samuel
N1 - Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.
PY - 2012
Y1 - 2012
N2 - Data from studies in animal models indicate that certain lipid metabolites, particularly diacylglycerol, ceramide, and acylcarnitine, disrupt insulin action. We evaluated the relationship between the presence of these metabolites in the liver (assessed by mass spectrometry) and hepatic insulin sensitivity (assessed using a hyperinsulinemic-euglycemic clamp with stable isotope tracer infusion) in 16 obese adults (body mass index, 48 ± 9 kg/m²). There was a negative correlation between insulin-mediated suppression of hepatic glucose production and intrahepatic diacylglycerol (r = -0.609; P = .012), but not with intrahepatic ceramide or acylcarnitine. These data indicate that intrahepatic diacylglycerol is an important mediator of hepatic insulin resistance in obese people with nonalcoholic fatty liver disease.
AB - Data from studies in animal models indicate that certain lipid metabolites, particularly diacylglycerol, ceramide, and acylcarnitine, disrupt insulin action. We evaluated the relationship between the presence of these metabolites in the liver (assessed by mass spectrometry) and hepatic insulin sensitivity (assessed using a hyperinsulinemic-euglycemic clamp with stable isotope tracer infusion) in 16 obese adults (body mass index, 48 ± 9 kg/m²). There was a negative correlation between insulin-mediated suppression of hepatic glucose production and intrahepatic diacylglycerol (r = -0.609; P = .012), but not with intrahepatic ceramide or acylcarnitine. These data indicate that intrahepatic diacylglycerol is an important mediator of hepatic insulin resistance in obese people with nonalcoholic fatty liver disease.
KW - Adult
KW - Carnitine/analogs & derivatives
KW - Ceramides/metabolism
KW - Diglycerides/metabolism
KW - Female
KW - Glucose/metabolism
KW - Humans
KW - Insulin Resistance
KW - Liver/metabolism
KW - Male
KW - Obesity, Morbid/metabolism
U2 - 10.1053/j.gastro.2012.03.003
DO - 10.1053/j.gastro.2012.03.003
M3 - Journal article
C2 - 22425588
VL - 142
SP - 1444-1446.e2
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 7
ER -
ID: 290034221